Elanco Q1 beats; FY25 revenue raised to $4.51-4.58B; debt paydown accelerated

Elanco Animal Health Inc

2025-Q1 EPS reported $0.13 revenue$1,193,000,000

Q1 revenue $1,193M (-1% reported, +4% organic CC); adj EPS $0.37 vs $0.34 YoY, above guidance.
FY25 revenue guidance raised to $4,510-$4,580M on FX tailwind; adj EBITDA guidance unchanged at $830-$870M.
Accelerating debt paydown: gross debt reduction $450-500M expected; net leverage target improved to 3.9x-4.3x.
Pet Health revenue $635M (-1%); Credelio Quattro ~10% share; Zenrelia in 11,000 clinics (35% penetration).
Q2 guidance: revenue $1,175-$1,195M, adj EPS $0.17-$0.21; organic constant currency growth 4-6%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.